Inotiv, Inc. and LifeNet Health have entered into a strategic collaboration that will integrate LifeNet’s TruVivo® platform into Inotiv’s Discovery and Translational Sciences (DSA) business. The partnership will allow Inotiv to offer human‑based in‑vitro models that use primary human hepatocytes and feeder cells, providing more physiologically relevant data for drug development.
TruVivo® is an all‑human 2D+ hepatic system that mimics liver microarchitecture and function. By incorporating primary human hepatocytes and feeder cells, the platform generates stable, reproducible models that can assess drug metabolism and toxicity with higher predictive value than traditional animal assays. The collaboration positions Inotiv to offer a broader range of human‑relevant assays, potentially reducing reliance on animal models and accelerating the translational pipeline.
The move aligns with the growing industry trend toward new‑approach methodologies (NAMs). Regulatory bodies such as the FDA and OECD are increasingly endorsing NAMs, and biopharmaceutical companies are seeking alternatives to animal testing for ethical, cost, and predictive reasons. By adding TruVivo® to its portfolio, Inotiv strengthens its competitive edge in the preclinical CRO market and signals a strategic pivot toward human‑relevant testing that can capture rising demand for NAMs.
Inotiv’s most recent financial results, covering fiscal year 2025 ending September 30 2025, show revenue growth in both its DSA and Research Models and Services (RMS) segments. The company reported a consolidated net loss that narrowed compared to fiscal 2024, while adjusted EBITDA improved, reflecting better cost control and operational leverage. A book‑to‑bill ratio of 1.05x for the DSA business indicates a healthy backlog and the capacity to absorb new service offerings such as TruVivo®.
Management emphasized the strategic importance of the partnership. Scott Daniels, Senior Vice President of Discovery & Translational Sciences, said the collaboration “will allow us to better align preclinical models with human biology and expand our human‑relevant tissue models beyond the liver.” Susan Campbell, General Manager of LifeSciences at LifeNet Health, added that the partnership “underscores our shared vision of transforming preclinical research through human‑relevant technologies.”
Financial terms of the collaboration, including licensing fees or revenue‑sharing arrangements, were not disclosed, and the timeline for full integration of the TruVivo® platform into Inotiv’s service offerings remains unspecified. However, the partnership is expected to broaden Inotiv’s human‑based assay portfolio and enhance its positioning in a market that is increasingly favoring NAMs.
The collaboration represents a strategic shift toward human‑based testing and expands Inotiv’s capabilities beyond traditional animal studies. By leveraging LifeNet’s proprietary platform, Inotiv can offer more physiologically relevant data, reduce reliance on animal models, and accelerate the drug development pipeline, positioning the company to capture growing demand for NAMs in the biopharma sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.